Literature DB >> 11112409

Interaction of Daxx, a Fas binding protein, with sentrin and Ubc9.

S W Ryu1, S K Chae, E Kim.   

Abstract

Sentrin is a ubiquitin-like protein that can covalently modify cellular proteins, and is a Fas binding protein that protects cells against anti-Fas induced cell death. However, the mechanism by which sentrin exerts its effect upon Fas-mediated apoptosis is not well known. Thus, this study examined the interaction of sentrin with Daxx. Sentrin interacted with Daxx but not with FADD when analyzed by yeast two-hybrid assay. In vitro translated Daxx bound to GST-sentrin fusion protein. FLAG-sentrin fusion protein was also coimmunoprecipitated with Daxx in BOSC23 cells. Also, Daxx interacted with Ubc9, an essential protein as a key conjugating enzyme. Amino acids 625-740 of Daxx, known as Fas binding region, was also mapped as sentrin and Ubc9 binding region. Colocalization of Fas, sentrin, and Ubc9 binding regions suggests the importance of that region upon the regulation of Daxx. Our data also demonstrated that sentrin could homooligomerize by protein-protein interaction. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112409     DOI: 10.1006/bbrc.2000.3882

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  PML is recruited to heterochromatin during S phase and represses DAXX-mediated histone H3.3 chromatin assembly.

Authors:  Prashanth Krishna Shastrula; Isabel Sierra; Zhong Deng; Frederick Keeney; James E Hayden; Paul M Lieberman; Susan M Janicki
Journal:  J Cell Sci       Date:  2019-03-26       Impact factor: 5.285

2.  SUMO-1 represses apoptosis signal-regulating kinase 1 activation through physical interaction and not through covalent modification.

Authors:  Yun-Suk Lee; Moon-Sun Jang; Jong-Soo Lee; Eui-Ju Choi; Eunhee Kim
Journal:  EMBO Rep       Date:  2005-10       Impact factor: 8.807

3.  Characterizing the N- and C-terminal Small ubiquitin-like modifier (SUMO)-interacting motifs of the scaffold protein DAXX.

Authors:  Eric Escobar-Cabrera; Mark Okon; Desmond K W Lau; Christopher F Dart; Alexandre M J J Bonvin; Lawrence P McIntosh
Journal:  J Biol Chem       Date:  2011-03-07       Impact factor: 5.157

4.  Negative modulation of androgen receptor transcriptional activity by Daxx.

Authors:  Ding-Yen Lin; Hsin-I Fang; Ai-Hong Ma; Yen-Sung Huang; Yeong-Shiau Pu; Guido Jenster; Hsing-Jien Kung; Hsiu-Ming Shih
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

5.  Daxx silencing sensitizes cells to multiple apoptotic pathways.

Authors:  Liuh-Yow Chen; J Don Chen
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

6.  SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Authors:  Sam R Holmstrom; Sergey Chupreta; Alex Yick-Lun So; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2008-06-18

7.  Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.

Authors:  Ingmar Meinecke; Antje Cinski; Anja Baier; Marvin A Peters; Berno Dankbar; Aline Wille; Andreas Drynda; Heidi Mendoza; Renate E Gay; Ronald T Hay; Barbara Ink; Steffen Gay; Thomas Pap
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-14       Impact factor: 11.205

8.  Poly-small ubiquitin-like modifier (PolySUMO)-binding proteins identified through a string search.

Authors:  Huaiyu Sun; Tony Hunter
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

9.  Cloning and identification of NS5ATP2 gene and its spliced variant transactivated by hepatitis C virus non-structural protein 5A.

Authors:  Qian Yang; Jun Cheng; Yan Liu; Yuan Hong; Jian-Jun Wang; Shu-Lin Zhang
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

Review 10.  DAXX in cancer: phenomena, processes, mechanisms and regulation.

Authors:  Iqbal Mahmud; Daiqing Liao
Journal:  Nucleic Acids Res       Date:  2019-09-05       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.